Clinical Trial Update: Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) [Phase 2]

View source ↗

Summary

Phase 2 trial of oral cMET inhibitor INC280 in EGFR wild-type advanced non-small cell lung cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• INC280 (cMET inhibitor) (savolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2024-03-20